Press Releases

Date Title and Summary View
Toggle Summary MediWound to Report Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call and Webcast on March 17, 2022
YAVNE, Israel , March 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the fourth
View HTML
Toggle Summary MediWound Announces Pricing of Public Offering of Ordinary Shares
YAVNE, Israel , March 03, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration, today announced the pricing of an
View HTML
Toggle Summary MediWound Ltd. Announces Proposed Public Offering of Ordinary Shares
YAVNE, Israel , March 02, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“Mediwound”), a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration, today announced that it intends to offer
View HTML
Toggle Summary MediWound to Present at Upcoming Investor Conferences in March
YAVNE, Israel , March 01, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that management would present at two upcoming investor conferences
View HTML
Toggle Summary MediWound Awarded a U.S. Department of Defense Research Grant for the Development of NexoBrid for the U.S. Army
Research Project Award is for the Development of NexoBrid as a Non-Surgical Solution for Field Care YAVNE, Israel , Feb. 17, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio therapeutic solutions for tissue repair
View HTML
Toggle Summary MediWound to Present at Upcoming Investor Conferences in February
YAVNE, Israel , Feb. 14, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that management would present at two upcoming investor conferences in
View HTML
Toggle Summary MediWound Announces Additional $9 Million in Funding from BARDA to Support NexoBrid BLA Resubmission and the Expanded Access Treatment Protocol
YAVNE, Israel , Feb. 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that the Biomedical Advanced Research and Development Authority
View HTML
Toggle Summary MediWound Announces Positive Topline Results From Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds
Primary Endpoint Met with Highly Statistically Significant Results No Observed Safety Issues Final Data R eadout Expected in Second Quarter of 2022 YAVNE, Israel , Jan. 24, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on
View HTML
Toggle Summary MediWound Announces Positive Initial Data from its U.S. Phase 2 Pharmacology Study of EscharEx Showing Effective and Rapid Debridement in Chronic and Hard to Heal Wounds
Data Demonstrate EscharEx Reduces Biofilm and Bacterial Burden EscharEx is Shown to be Safe with No Observed Safety Issues YAVNE, Israel , Dec. 20, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation
View HTML
Toggle Summary MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study
Topline Data Expected in the First Quarter of 2022 YAVNE, Israel , Dec. 06, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced it
View HTML